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ABSTRACT
Introduction: This case report adds supportive
evidence to the development of acute angle-
closure glaucoma (AACG), a rare but serious
adverse effect following the use of topiramate
(TPM) for a severe headache.
Case Report: A 25-year-old female reported
with severe headache, suspected to be
migraine, and was started on TPM 25 mg/day
on the first day. However, she presented at the
emergency clinic of a hospital with sudden
blurring of vision and colored halos 5 days
after stopping the drug, i.e., day 8. She was
subjected to ophthalmic examination and was
diagnosed with AACG. The intraocular pressure
(IOP) was found to be elevated and she was
hence started on acetazolamide 500 mg
instantly, maintained on tablet acetazolamide
250 mg four times a day (QID), pilocarpine 2%
eye drops QID, travoprost 0.004% once a day
(OD), and dorzolamide 2% eye drops three
times a day (TID). After a week’s treatment,
there was rapid improvement with return of
IOP to normal.
Conclusion: TPM-induced AACG is a rare
serious adverse event leading to blindness but
is preventable, when diagnosed early and by
instituting appropriate treatment.
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INTRODUCTION
Migraine is typically characterized by a
pulsating headache with or without aura,
nausea, and vomiting. The drugs commonly
used in acute migraine attacks are sumatriptan
(which is one of the triptans chemically
grouped under serotonin agonists) and ergot
alkaloids, while propranolol and calcium
channel blockers are used prophylactically.
However, recently topiramate (TPM), an anti-
epileptic drug, has gained popularity as a first
line drug for use in prophylaxis of migraine [1].
The use of TPM for epilepsy and migraine has
been approved by the US Food and Drug
Administration (FDA) and it also has a number
of ‘‘off-label’’ indications, such as bulimia
nervosa, alcohol dependence, smoking, and
possibly a depressive phase in bipolar disorders
[2].
The most significant adverse effects
associated with TPM include psychomotor
slowing, difficulty in concentration,
somnolence, and fatigue. Additional non-
specific central nervous system (CNS) adverse
effects are dizziness, confusion, and memory
problems. The dose and duration-dependent
use include renal stones, weight loss, and
paresthesia [3]. Recently, evidence has been
accumulating on a rare but serious adverse
event on TPM-induced acute myopia with
acute angle-closure glaucoma (AACG) both as
spontaneous case reports and case series [4–7]. A
‘‘black box’’ warning was, therefore, issued by
the FDA in 2004, regarding its potential to
induce AACG as a precaution for practicing
physicians [8].
The World Health Organization (WHO) has
estimated that India has a 1% prevalence of
blindness. Of the estimated 8.9 million blind in
India, 12.8% are due to glaucoma [9]. While
there is population-based data available on
primary glaucoma from South Asia, especially
India, data on secondary drug-induced
glaucoma are lacking, except for spontaneous
reports [10]. The authors report an observation
of a case, where a female patient developed
AACG after 8 days, following TPM 25 mg/day,
once a day (OD), for 3 days as an adverse
reaction to TPM.
CASE REPORT
A 25-year-old female presented with severe
headache and was diagnosed with migraine.
She was started on TPM 25 mg/day; however,
she stopped the treatment after 3 days without
consultation as her headache was not relieved.
After 5 days of stopping the treatment with
TPM, she presented at the emergency clinic of a
hospital with complaints of blurred vision and
severe pain in both the eyes, which were of a
few hours in duration. She also complained of
colored halos and headache associated with
nausea with no family history of eye-related
disorders. On ophthalmic examination, the
visual acuity was found to be 3/60 in both the
eyes, and did not show improvement in visual
acuity in the pinhole test. There was bilateral lid
edema, ciliary congestion, and chemosis. Both
anterior chambers were found to be shallow,
appeared occluded in the periphery, and
pupils were reactive. Applanation tonometry
revealed high intraocular pressure (IOP) of 34
and 32 mmHg, in the right and left eyes,
respectively (Fig. 1).
A diagnosis of AACG, precipitated following
oral administration of TPM, was made. While,
laser peripheral iridotomy would have been an
ideal procedure for AACG, due to presence
of choroidal effusion along with anterior
migration of anterior structures this treatment
option was not considered in this case. She was
hence started on acetazolamide tablets 250 mg
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four times a day (QID), pilocarpine 2% eye
drops QID, travoprost 0.004% OD, and
dorzolamide 2% eye drops three times a day
(TID). Since she had already stopped TPM, she
was advised not to take it again and was
reviewed the next day. The repeat ophthalmic
examination on the second day showed
improved vision (6/60) in both the eyes,
reduction in conjuctival chemosis, and
improved depth of anterior chamber, while
it continued to be shallow peripherally.
IOP measurements were repeated using
applanation tonometry and were found to be
20 and 18 mmHg, in the right and left eyes,
respectively. On the third day, her vision
improved to 6/12 in the right eye and
6/6 partial (p) in the left with IOP 10 and
14 mmHg, respectively. The ophthalmoscopic
examination of disc and macula was normal in
both the eyes. Subsequent examination on the
fifth day showed improved visual acuity 6/6 p in
both the eyes and IOP was 14 and 12 mmHg
and the anterior chamber appeared well
formed.
She was advised to taper the anti-glaucoma
medication and was examined a month later
when her visual acuity was 6/6, with IOP
14 mmHg in both the eyes and was then
advised via evaluation by a glaucoma specialist.
All procedures followed were in accordance
with the ethical standards of the responsible
committee on human experimentation
(institutional and national) and with the
Helsinki Declaration of 1975, as revised in
2008. Written informed consent was obtained
from the patient for which identifying
information is included in this case report.
DISCUSSION
There have been 115 case reports of ocular side
effects, 86 cases of secondary angle-closure
glaucoma, and 7 cases of permanent visual
loss reported with TPM, suggesting an
association between acute onset of AACG after
TPM therapy [11, 12]. The present case report
adds evidence to show symptoms of acute onset
of blurred vision associated with ocular pain to
be due to adverse event associated with TPM
prescribed for migraine. The ciliary body edema,
uveal effusion, and relaxation of zonules along
with anterior rotation of the ciliary body
resulting in forward shift of the iris-lens
apparatus are reported to contribute to TPM-
induced AACG. In addition, these latter effects
are said to produce shallow anterior chamber,
leading to an increase in IOP and thus
precipitating the acute glaucomatous attack
secondary to the increase in IOP.
TPM primarily introduced for the treatment
of epilepsy is said to act by modulation of the
voltage gated sodium channels, strengthening
gamma-aminobutyric acid (GABA)ergic activity
and reduction in the effects of activation of
glutamatergic receptor of alpha-amino-3-
hydroxy-5-methyl-4-isoxazolepropionic acid
(AMPA)-kainate subtype. Interestingly, TPM is
also known to share weak carbonic anhydrase
(CA)-inhibitor activity like acetazolamide,
hence paradoxically, is an effective anti-
glaucoma drug. However, as a CA inhibitor it
is linked with the occasional development of
renal calculi and also being a sulfa-based drug
Fig. 1 A photograph of normal (a) and glaucomatous (b) eyes
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by itself is reported to induce AACG through an
idiosyncratic reaction [13, 14].
The potential to cause glaucoma may,
therefore, be attributed to a mechanism
independent of the well-known
pharmacodynamic effects involved in anti-
convulsant activity of TPM. Several studies do
report on the genetic basis of primary open-
angle glaucoma (POAG) and juvenile onset
open-angle glaucoma (JOAG) [15, 16]. The
genetic predisposition may also be considered
as a cause for AACG in some individuals,
although several reports propose on usage of
TPM to induce secondary AACG [4, 5, 17, 18].
It is to be noted that ideally patients
presenting with increased IOP will be subjected
to ophthalmic examination like gonioscopic
examination with ultrasound biomicroscopy
which are recommended routinely [5, 18].
However, these were not carried out in this
particular patient, which may be due to the fact
that the presenting history clearly revealed a
diagnosis of TPM-induced AACG. Thus, the
presenting nature of the symptoms has possibly
warranted initiation of anti-glaucoma therapy
immediately. The other tests for glaucoma work-
up like Glaucoma diagnosis-Variable Cornea
Compensation (GDx-VCC) and Optical
Coherence Tomography (OCT), which are both
expensive and not mandatory in the acute phase
of AACG, were not carried out.
It is to be noted that ideally the present case
could have been subjected to complete
ophthalmic examination to include gonioscopic
examination along with ultrasound
biomicroscopy and iris configuration as
recommended routinely [5, 18]. The diagnosis in
this case was primarily based on detailed history
taking as these tests are not carried out routinely
due to economic constraints in the Indian
context.
While TPM was discontinued, this patient
was prescribed miotics like pilocarpine as eye
drops, which is reported to be of doubtful
benefit in the treatment of TPM-induced
glaucoma along with sulfa drugs like
acetazolamide and dorzolamide. It is hence
important to note that administration of these
medications appears inappropriate as these are
likely to exacerbate the condition and could
have been avoided. In addition, the treatment
regimen did not include anti-inflammatory
medication such as prednisolone as a topical
steroid in this case [7, 18].
It is recommended that treatment with TPM
for migraine be started with a low dose and
gradually increased to the required dosage
depending on improvement of the condition
and patient tolerability profile. But in this
particular patient, reaction appeared to be
independent of the dose and duration as the
patient had received the minimum therapeutic
dose of 25 mg/day and TPM reaction developed
within a short duration of treatment [5, 19].
While this is difficult to explain, despite
discontinuation of TPM, the cumulative effect
may be considered responsible for development
of AACG. The mechanism by which TPM causes
ciliary body swelling and anterior rotation of
the ciliary body is still not clear. The most
shared hypothesis remains to be idiosyncratic
reaction [13, 14]. Based on the above
information, it may be suggested that it is
important and appropriate to avoid treatment
of AACG with miotics and medications
chemically related to sulfa drugs. Initiation of
treatment with TPM over 3 days induced AACG
on day 8 and instituting treatment reversed the
signs and symptoms of AACG and patient was
normal after discontinuation of TPM. Based on
this fact, the eventual causality as TPM-induced
AACG can be confirmed.
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However, in this particular patient although
history of medication intake revealed treatment
with anti-cholinergics for other reasons, patient
did not exhibit eye symptoms. Therefore, the
mechanisms implicated in development of
AACG in this case need further evaluation.
Lastly, the authors wish to point out that the
patient in this case is 25 years old, which is
young for POAG as the onset is normally seen
after 40 years of age [2]. The limitations of this
study were that this is a single case report and
not a case series, which are preferred. In
addition, causality using a standard scale was
not used to confirm association between the
offending drug and adverse reaction.
CONCLUSION
TPM is frequently used in the treatment of
migraine and is reported to increase IOP and as
a result has a potential to precipitate AACG in a
genetically predisposed person. A single dose
may precipitate AACG as an idiosyncratic
reaction which is a rare but a very serious
adverse reaction and may progress to blindness.
It is, therefore, recommended that the
physician before prescribing TPM should warn
and advise the patient to report any cases of
visual disturbances immediately. It is also
advisable to monitor the IOP at baseline
before initiating treatment with TPM and
regularly at weekly intervals thereafter for a
month from the time of commencement of
medications to prevent glaucoma as one of its
serious adverse reactions.
Although this is a widely reported adverse
effect of TPM, there are a few questions which
remain unanswered. One aspect that could be
examined is how exactly sulfa-derived
medications such as TPM can cause swelling of
ciliary body and eventual anterior rotation of
ciliary body. It would be worth investigating to
see if patients who developed AACG with TPM
showed a similar reaction to other sulfa-
containing compounds. However, in this
patient AACG was precipitated specifically
with TPM. In addition, considering age of this
patient it is unlikely to be POAG.
With recent advances in the field of drug
discovery and development, there appears to be a
possibility to minimize such undesirable,
unexpected, and serious adverse events using
safer treatment options in patients with
migraine. Alternatively, careful and regular
monitoring of patients receiving TPM is
important. Finally, with exponential
advancement in pharmacogenetics, every patient
taking TPM could be considered as a potential
candidate for developing AACG, and be screened
adequately and appropriately using suitable
biomarkers to prevent serious adverse events.
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